Graft Failure after Allogeneic Hematopoietic Cell Transplantation  by Mattsson, Jonas et al.
Biology of Blood and Marrow Transplantation 14:165-170 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1401-0001$32.00/0
doi:10.1016/j.bbmt.2007.10.025Graft Failure after Allogeneic Hematopoietic Cell
Transplantation
Jonas Mattsson,1 Olle Ringden,1 Rainer Storb2
1Center for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Karolinska Institutet,
Karolinska University Hospital Huddinge, Stockholm, Sweden; 2The Fred Hutchinson Cancer Research
Center and the Department of Medicine, University of Washington School of Medicine, Seattle, Washington
Correspondence and reprint requests: Olle Ringden, MD, PhD, Karolinska Institutet, Division of Clinical Immunology,
Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden (e-mail: Olle.Ringden@ki.se).
ABSTRACT
Graft failure is a significant complication following allogeneic hematopoietic cell transplantation (alloHCT). It
may result from rejection caused by recipient T cells, natural killer (NK) cells, or antibodies. It is increased in
HLA-mismatched grafts, unrelated grafts, T cell-replete transplants, sensitized patients, and in patients treated
with reduced-intensity conditioning (RIC). In recipients of unrelated grafts, graft failure is increased in patients
receiving major AB0 blood group mismatched transplants (P 5 .008). Recent data also suggest that donor-spe-
cific antibodies to CD341/VEGFR-21 cells may be involved in graft failure after alloHCT. Graft failure may be
overcome by more intensified conditioning, increased cell dose, or more effective immunosuppression. With
more frequent use of RIC, cord blood grafts and other HLA-mismatched transplants, graft failure is an increas-
ing problem after alloHCT.
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Graft failure or graft rejection after allogeneic he-
matopoietic cell transplantation (alloHCT) may be
manifested as either lack of initial engraftment of donor
cells, or loss of donor cells after initial engraftment. In
the latter case, autologous recovery may appear, or al-
ternatively, marrow aplasia and pancytopenia may de-
velop. Rejection is a major cause of graft failure, and
is because of recipient immune response against donor
immunohematopoietic cells. Rejection is supported by
the presence of recipient lymphocytes, preferentially T
cells, and the absence of donor cells in blood and mar-
row. Graft failure may also be because of other causes,
such as viral infections, specifically, cytomegalovirus
(CMV), human herpes virus type 6 (HHV6), and par-
vovirus. Drug toxicity and septicemia can also induce
graft failure. In the latter case of graft failure, persis-
tence of donor cells with or without the presence of
recipient cells can be detected in blood and marrow.
Several immunologic mechanisms may cause graft
failure. Most commonly, it is because of immune re-cipient T cells, although natural killer (NK)-mediated
rejection also has been demonstrated in animal models
[1-5]. NK-mediated allograft rejection, to some ex-
tent, can be overcome by cyclophosphamide (Cy) or
total-body irradiation (TBI) administered before
transplantation and antimetabolites, such as metho-
trexate (MTX), given after transplantation [6]. Fur-
ther, pretreating canine recipients of dog leukocyte
antigen (DLA)-mismatched marrow with an antibody
to an adhesion molecule, CD44, allowed for sustained
engraftment in most cases [1]. Whether antibodies can
cause rejection is controversial [7-9]. In mice,
antibody-mediated rejection resulted in rejection
within 3 hours in allosensitized recipients of major his-
tocompatibility complex (MHC) mismatched bone
marrow [10] in a similar way as antibody-mediated hy-
peracute rejection of renal allografts. In contrast, stud-
ies in a large animal model, transfusion-sensitized
random-bred dogs, showed successful marrow en-
graftment in the presence of circulating cytotoxic anti-
bodies against donor cells [11]. These results point
toward cellular rather than humoral mechanisms165
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With the use of reduced-intensity conditioning
(RIC) and a wider application of HLAmismatched do-
nors, graft failure has become an increasing problem.
This article will summarize our present knowledge of
graft failure/rejection in alloHCT with a focus on re-
cent advances.
RISK FACTORS FOR GRAFT FAILURE
Of major importance for allograft rejection is
disparity between recipient and donor within the
MHC. In patients with leukemia receiving myeloabla-
tive conditioning, the rejection rate was 0.1% in pa-
tients given HLA-identical sibling transplants,
compared to 5% in those given HLA-mismatched
grafts [12]. Recipients of stem cells from unrelated do-
nors also have an increased risk of graft failure, com-
pared to patients receiving grafts from HLA-
identical siblings. Using unrelated donors, HLA class
I disparity between donor and recipient was associated
with an increased risk of rejection [13].
Patients sensitized by blood transfusions, but also
by pregnancy, are at increased risk of rejection. In
immunized patients, rejections are likely caused by
memory T cells, although some investigators have
implicated antibodies that recognize major or minor
histocompatibility antigens on donor cells. Patients
with nonmalignant blood disorders, such as aplastic
anemia and thalassemia major, who have been treated
withmultiple transfusions before transplant, had rejec-
tion probabilities in the range of 5% to 60% in earlier
transplant series [14,15]. A low marrow cell dose was
reported to be associated with an increased probability
of graft failure [16]. Transfusion-induced sensitization
can be largely averted in the MHC-identical setting by
leukodepletion [17] and in vitro irradiation [18,19] of
transfusion products. An increased risk of graft rejec-
tion is also seen in recipients of T cell- depleted
(TCD) grafts [20].
RIC is used in elderly patients and those with
comorbidity who cannot tolerate full myeloablative
conditioning [21,22]. However, with lower doses of
chemoradiation therapy, the host immune system
may persist, resulting in an increased risk of allograft
rejection. In this setting, the intensity of the condition-
ing seems important for the frequency of graft failure.
Thus, using nonmyeloablative conditioning, 6 of 24
patients experienced graft failure compared to 1 of
34, using more intense chemotherapy in the setting
of RIC (P 5 .02) [23].
HLA-HAPLOIDENTICAL TRANSPLANTS
Only 1/3 of the patients have HLA-identical
sibling donors. With an unrelated donor pool of 10
million volunteer donors, 80% of Caucasian patients
have access to well-matched unrelated donors.For the remaining patients, HLA haploidential or
partially mismatched related donors are readily avail-
able possibilities in most patients, especially in chil-
dren, where parents may be motivated to serve as
donors. HLA haploidentical donors have been used
also in adults, using effective TCD and overcoming
graft rejection with a megadose of stem cells [24].
It has been postulated that, in this setting, graft
rejection may be overcome by donor NK cells, which
may eliminate recipient immunocompetent cells. In
experimental animals, it has been known for a long
time that adding T cells to the marrow inoculum
could overcome the MHC barrier to engraftment
[25,26].
CORD BLOOD TRANSPLANTS
Almost all patients are potentially eligible for cord
blood transplants, because tissue typing requirements
are less stringent, and up to 2 HLA-antigen mis-
matches are acceptable [27,28]. Engraftment is delayed
and graft failure is increased using cord blood trans-
plants compared to bone marrow [29]. The cell dose
is important for outcome and should be above 2 
107 nucleated cells/kg recipient weight. When the
cell dose is too low, double cord blood transplants
may overcome this problem [30]. Today, using dif-
ferent strategies, it is possible to find a graft for all
patients in need of alloHCT. Therefore, using
HLA-mismatched cord blood transplants, antibody-
mediated microcytotoxicity using recipient serum
and donor lymphocytes may need to be analyzed be-
fore transplant in multiply transfused recipients. A
positive test raises a flag, heralding either the risk
of antibody-mediated or, more likely, T cell-based
acute rejection.
MAJOR AB0 BLOOD GROUP MISMATCH AND GRAFT
FAILURE
Among 224 leukemic patients receiving unrelated
grafts, it was found that patients with major AB0
blood group mismatches had an incidence of graft
failure of 7.5%, compared to 0.6% in recipients
of minor AB0 mismatched or AB0 compatible grafts
(P 5 .02) [31]. In multivariate analysis, major AB0
mismatch (P 5 .008) and HLA allele mismatch
(P 5 .03) were associated with graft failure.
This provocative observation has as yet not been
reported by others [32]. Although red blood cell anti-
gens are not known to act like transplantation antigens
and their expression is restricted to red blood cells and
their more mature precursors, it is conceivable that
transplantation methods used to overcome the ABO
barriers might contribute to graft failure. For example,
red blood cell depletion of the graft might lead to los-
ses of both stem cells and T lymphocytes thought to be
critical for sustained engraftment.
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Recipient T and NK cells are presumed to be the
primary effector cells that mediate rejections after al-
loHCT, but other immunologic mechanisms may
also contribute to the elimination of donor cells.
After organ transplantation, alloantibodies may
mediate a substantial proportion of organ allograft re-
jection episodes, contributing to both early and late
graft loss [33,34]. Antibody-mediated rejection may
also occur after alloHCT [7]. Some studies have also
indicated an inferior survival because of graft failure
in patientswith a positive crossmatch prior to alloHCT
[35].
It has recently been indicated that CD341/
VEGFR-21 cells from adult bone marrow or cord
blood may generate both hematopoietic and endothe-
lial cells in vitro [36]. This cell population also seem to
be of importance for engraftment after alloHCT [37].
In a recent study by Nordlander et al [38], we stud-
ied 19 patients without and 11 with rejection after al-
loHCT and 20 nontransplanted healthy individuals.
Sera taken pre- and posttransplantation from patients
receiving alloHCT were studied for the presence of
donor CD341/VEGFR-21 cell-specific antibodies. A
significantly higher numbers of patients with rejection,
9 of 11 (81 %), compared to 1 of 19 (5%) (P 5 .001)
without rejection had antibodies against donor
CD341/VEGFR-21 cells, but not CD342/VEGFR-
22 cells. In 8 of the patients studied, antibodies against
donor CD341/VEGFR-21 cells were detected prior
to transplantation. Purified IgG fractions from pa-
tients who rejected their grafts, but not controls signif-
icantly decreased the ability of these cells to form
hematopoietic and endothelial colonies. The specific
antigen for these antibodies is currently unknown.
In conclusion, donor-specific antibodies to
CD341/VEGFR-21 cells may be involved in graft
failure after alloHCT.
MOLECULAR DIAGNOSIS OF ENGRAFTMENT
PCR amplification of variable number tandem re-
peats (VNTR) loci enables a sensitive technique to
identify donor and recipient cells after alloHCT
[39,40]. For instance, using immunomagnetic beads,
T cells, B cells, and myeloid cells and others can be
separated to increase the sensitivity and specificity of
the method [41]. An increase in recipient T cells pre-
cedes graft rejection [42]. In the setting of RIC, it
may be especially valuable to follow T cell chimerism,
where high numbers of recipient T cells on day 128
may be an indicator of graft rejection [43-45].
PREVENTION OF GRAFT FAILURE
In patients with an increased risk of graft failure,
graft rejection can be overcome by more intensifiedconditioning regimens, such as those using total lym-
phoid irradiation, thoracoabdominal irradiation, or
TBI [46]. In patients with thalassemia major with class
III disease receivingmultiple transfusions and with cir-
rhosis, the risk of rejection was 30% in HLA-identical
siblings receiving conditioning with busulphan and Cy
[47]. By adding hydroxurea, azathioprine, and fludara-
bine (Flu) to this regimen, the risk of rejection de-
creased to 8%. Increasing the cell dose by giving
donor buffy coat transfusions, or giving granulocyte–
colony-stimulating factor (G-CSF)-mobilized periph-
eral blood stem cells (PBSC) instead of bone marrow,
may also reduce the rates of graft rejection. [48,49].
PBSC have a 10-50-fold higher T cell and NK cell
dose compared to bone marrow, and a 2-fold higher
CD34 cell dose [50]. PBSC is the stem cell source of
choice using RIC.
The use of antithymocyte globulin (ATG) in com-
bination with Cy during conditioning in patients with
aplastic anemia (AA) may increase the immunosup-
pressive effect of the conditioning and result in a lower
incidence of graft rejection with corresponding en-
hanced rates of overall survival (OS) [51,52].
CELLULAR THERAPY TO OVERCOME GRAFT FAILURE
Donor lymphocyte infusions (DLI) have been in-
creasingly used to treat relapse, especially molecular
relapse, in patients with chronic myelogenous leuke-
mia (CML), but may also be used to overcome rejec-
tion in cases of decreasing donor T cell chimerism
[53,54]. Side effects of DLI include graft-versus-host
disease (GVHD) and, in some cases, marrow aplasia.
DLI have a potent immunologic effect and, combined
withmonoclonal anti CD3 receptor antibody (OKT3),
may reverse an impending rejection, even in patients
who recieve 5 of 6 HLA antigen mismatched unrelated
grafts [55]. In patients with AA undergoing rejection,
conditioning with a combination of Cy and ATG be-
fore second alloHCT has resulted in sustained grafts
in most cases [56].
In patients with continued poor graft function in
the absence of graft rejection, a boost of donor stem
cells without additional preparative chemotherapy
may improve graft function [57-59]. Nine of 15 (60%)
evaluable patients became transfusion-independent
within 1 month after a boost marrow was given [59].
Because boost marrow may induce GVHD, TCD of
the stem cells can preventGVHDand improve survival
in some patients [60].
In patients with fulminant rejection, retransplanta-
tion is necessary, using the same or another donor.
Conditioning should preferentially differ from that
used at the first transplant to avoid unnecessary toxic-
ity. Because of an increased risk of rejection and
GVHD with repeated transplants, ATG or Campath
may be considered during conditioning. A high
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For immune modulation and to enhance engraftment,
cotransplantation with mesenchymal stem cells has
recently been evaluated in pilot studies [61].
Presently, the mechanism causing graft failure af-
ter cord blood transplants is not well defined. If it is
mediated mainly by recipientT cells, it may be over-
come by ATG, increasing the cell dose and/or the in-
tensity of the conditioning regimen. In immunized
patients, it has been speculated to be caused by anti-
bodies against HLA antigens.
IMMUNE ABSORPTION
In the case of alloimmune patients, HLA-specific
antibodies may be modulated by high-dose intrave-
nous immunoglobulin [62]. The combination of
immune absorption and treatment with anti-B cell an-
tibodies might be able to remove anti-HLA antibodies
[63]. This method has successfully been employed in
renal transplant recipients with anti HLA antibodies.
Immune absorption to remove anti-HLA antibodies
has also been employed before alloHCT in a few anec-
dotal cases.
In 1 patient with antibodies against donor CD341/
VEGFR-21 cells we have tried to change the condi-
tioning therapy to decrease or remove these antibodies
(Mattsson et al, unpublished data). A 2.5-year-old
patient with hemophagocytic lymphohistiocytosis
(HLH) showed increasing recipient chimerism after
alloHCT. At 1 year the patient showed .95% recipi-
ent cells in all cell lineages. Antibodies to CD341/
VEGFR-21 donor cells were detected. The patient
was retransplanted with the same donor because no
other donor was available. The conditioning therapy
consisted of Flu combined with Cy and 5 days with
plasmapheresis. In microcytotoxicity assay patient
sera showed 100% lysis of CD341/VEGFR-21 donor
cells before plasmapheresis, but no lysis after 5 days of
plasmapheresis. After alloHCT, antibodies against do-
nor CD341/VEGFR-21 cells were detected on day
114. The patient again showed increasing recipient
hematopoietic chimerism. At 4 weeks, a bone marrow
aspirate showed 95% recipient cells among CD341
cells and 80% recipient T cells. Despite this, the pa-
tient developed grade III acute GVHD (aGVHD)
and eventually converted to full donor chimerism in
all lineages.
In summary, graft rejection is mainly caused by im-
munized T cells, although other mechanisms may also
exist. Rejectionmay be overcome by increasing the cell
dose, or by more intense immunosuppression and con-
ditioning prior to transplantation. Because of the
wider use of HLA-mismatched grafts and RIC, graft
failure is an increasing problem in clinical alloHCT.
Chimerism studies enables early diagnosis and in
some cases intervention with or without immunosup-pression and infusion of additional donor cells. In cases
of fulminant rejection, retransplantation is necessary.
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